Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks

Chinese Medical Journal

Volumn 117, Issue 3, 2004, Pages 347-352

  Li, Li ^a   Wei, Fei Li ^a   Mei, Shan ^a   Feng, Xin ^b   Yao, Jun ^b   Jin, Xia ^c   Cao, Yun Zhen ^a  

^a National Center for Tuberculosis Control and Prevention   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Activation markers; CD4+ T cell counts; HIV AIDS; Viral load

Indexed keywords

BIOLOGICAL MARKER; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; EFAVIRENZ; HLA DR ANTIGEN; INDINAVIR;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CELL SEPARATION; CHINESE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL PARAMETERS; IMMUNOREACTIVITY; LYMPHOCYTE COUNT; MALE; METHODOLOGY; MONONUCLEAR CELL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; THAWING; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADP-RIBOSYL CYCLASE; ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD38; CD4-CD8 RATIO; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HLA-DR ANTIGENS; HUMANS; INDINAVIR; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OXAZINES; VIRAL LOAD;

EID: 1842502786     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Michaels SH, Clark R, Kissinger P, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 1999; 339:405-406.
2. Cao Y, Zhang FJ, Mei S, et al. The first clinical trial using triple therapy Combivir plus Indinavir in Chinese individuals with HIV infection. Chin J Intern Med 2002;41:109-113.
3. Riddler S, Kahn J, Martin G, et al. Durable HIV suppression and tolerability with Efavirenz ( EFV) + Indinavir (IDV): Results at 132 weeks ( study 003-cohort IV). 7th Conference on Retroviruses and Opportunistic Infections. Jan 30-Feb 4, 2000, San Francisco.
4. Cao Y, Zhang FJ, Zhou ZQ, et al. Clinical update on 24 weeks combination therapy with once a day Efavirenz and three time a day Indinavir in HIV-1 infected patients in China. The 1st IAS conference on HIV pathogenesis and treatment, Buenos Aires, July 8-1, 2001.
5. Kaufmann GR, Zaunders JJ, Cunningham P, et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000;14:2643-2651.
6. + cell count, soluble immune activation markers, or combination of HLA-DR and CD38 expression. J Acquir Immun Defici Syndr Hum Retrovirol 1997;16:83-92.
7. Howard M, Grimaldi JC, Bazan JF, et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science 1993;262:1056-1059.
8. Clinical Diagnosis, treatment and care of AIDS. Beijing: People's Health Publishing House; 2001:1-13.
9. Cao Y, Qin LM, Zhang LQ, et al. Virological and immunological characterization of long-term survivors with infection of HIV-1. New Engl J Med 1995;332:201-208.
10. - phenotype : Comparison of statistical methods of measurement. J Acquir Immune Defici Syndr 1999; 22:19-30.